MeSH tree: C10.228.854
The United States is experiencing the worst year for measles cases in more than three decades, with nearly 2,000 cases confirmed by the Centers of Disease Control and Prevention (CDC). There have been 49 outbreaks spanning ...
Dec 22, 2025
0
22
Two-year-old German boy, Oliver Staub, lay in a Mexico City hospital bed awaiting death.
Dec 19, 2025
0
1
Researchers at McMaster University have developed a new database that brings together more than 100 years of historical epidemiological data from across Canada, which will help to predict future patterns of infectious disease.
Dec 18, 2025
0
0
Cedars-Sinai investigators have discovered a healing mechanism that could one day be harnessed to help treat patients with spinal cord injuries, stroke, and neurological conditions such as multiple sclerosis. Their study, ...
Dec 17, 2025
0
27
ALS is a debilitating paralytic disease characterized as the death of upper and lower motor neurons. Fortunately, ALS is relatively rare, with an incidence rate of 1.6 per 100,000 adults, resulting in about 30,000 cases in ...
Dec 16, 2025
0
0
A Northwestern Medicine study has shed light on a critical molecular mechanism underlying amyotrophic lateral sclerosis (ALS), according to findings published in the journal Neuron.
Dec 15, 2025
0
30
Pakistani authorities on Monday launched the final nationwide anti-polio vaccination campaign of the year, aiming to protect 45 million children after more than two dozen cases of the potentially paralyzing disease were reported, ...
Dec 15, 2025
0
0
Friedreich's ataxia (FA) is a rare but devastating genetic disorder. Those with the condition are often diagnosed between 5 and 15 years of age and live only into their 30s or 40s. There is no widely approved treatment that ...
Dec 10, 2025
0
21
Using machine learning models, researchers at Michigan Medicine have identified a potential way to diagnose amyotrophic lateral sclerosis, or ALS, earlier from a blood sample, a study suggests.
Dec 9, 2025
0
31
The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal muscular atrophy (SMA) in patients 2 years and older with confirmed mutation in the survival motor neuron ...
Dec 8, 2025
0
0
